Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company's platform of unique molecular entities selectively affects inflamed nociceptors.

Nocion Therapeutics is a biopharmaceutical company developing novel treatments for silencing neurons. The company’s platform of unique molecular entities selectively affects inflamed nociceptors. Treatment using this approach aims to provide more durable and robust local analgesic effects while minimizing numbness or paralysis and other systemic off-target effects. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons including chronic cough, pain and itch.

F-Prime Capital

Partners Innovation Fund

Mission BioCapital

Canaan Partners

Nocion Therapeutics, Inc.

“We scrambled, got back, revived from the dead, if you will, and then worked again to bring in the right syndicate for this."

Boston-area biotech Nocion Therapeutics, Inc. has raised $62 million to bring its capsule-based inhaler toward Phase III testing, CEO Rick Batycky told Endpoints News. 

The startup is attempting to treat chronic cough, a condition that lasts at least eight weeks and has become more stigmatized as a result of the Covid-19 pandemic. 

"It can make you feel like a social outcast,” said Julie Grant, a general partner at Nocion investor Canaan Partners.

More on how Nocion plans to treat chronic cough with a different approach than GSK (by way of Bellus) and Merck: 

#cough #drugdevelopment #biotech #venturecapital 

We are thrilled to announce we have raised $62 million in Series B funding which will allow us to complete a Phase 2b study in Chronic Cough. Thank you to our new and existing investors for making this possible. 
https://lnkd.in/esqVrNTZ


COM:NOCIONTX

Nocion Therapeutics

Analysis Not Available